Table 3.

Surgical outcomes between radical surgery with extensive upper abdominal procedures and standard surgery

Variable	Radical surgery group (n = 112)	Standard surgery group (n = 241)	P value*
Residual disease, in overall			<0.001
0 cm	46 (41.1 %)	0 (0 %)
0.1–0.5 cm	46 (41.1 %)	27 (11.2 %)
0.5–1 cm	15 (13.4 %)	78 (32.4 %)
>1 cm	5 (4.5 %)	136 (56.4 %)
Residual disease in upper abdomen			<0.001
0 cm	76(67.9 %)	0(0 %)
0.1–0.5 cm	24(21.4 %)	30(12.4 %)
0.5–1 cm	10(8.9 %)	75(31.1 %)
>1 cm	2(1.8 %)	136(56.4 %)
Estimated blood loss			<0.001
Median volume	800 ml	600 ml
(range)	(100–4000)	(100–3000)
Intraoperative blood transfusion			<0.001
Median volume	800 ml	400 ml
(range)	(0–3200)	(0–2400)
Operative time			<0.001
Median	171 min	124 min
(range)	(75–360)	(51–318)
ICU stay			0.018
Yes	28 (25.0 %)	35 (14.5 %)
No	84 (75.0 %)	206 (85.5 %)
Length of hospitalization			<0.001
Mean	19.96 days	10.39 days
(range)	(4–190)b	(4–42)

^*Tested by Chi-square or Mann–Whitney U.^b33 patients (29.5 %) in radical surgery group participated in a phase II clinical trial on intraperitoneal chemotherapy and were assigned to receive IP chemotherapy for 4 cycles weekly post operative in hospital, whereas only 7 patients (1.7 %) in standard surgery group participated in this trial and received IP chemotherapy. One patient stayed in hospital for 190 days because she received all the cycles of IP and IV chemotherapy in hospital